Sofinnova Partners

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

MD Start SA is a Swiss-based incubator and fund focused on the medical technology sector, established in 2009. The company specializes in transforming innovative medical ideas into viable business ventures, providing comprehensive support from project creation to operational development. It partners with prominent organizations in the industry, including Medtronic and Sofinnova Partners, to facilitate the growth of medical device start-ups. By employing both strategic and hands-on approaches, MD Start aims to guide these projects through the investment stage and into commercial development, helping to bring new medical technologies to market.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Auris Medical is a biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of disorders affecting the inner ear and central nervous system. Its advanced clinical programs include Keyzilen for acute inner ear tinnitus and AM-111 for acute inner ear hearing loss. The company is also working on AM-125, which is in Phase 2 trials for the intranasal treatment of acute peripheral vertigo, and AM-201, in Phase 1b trials aimed at preventing side effects associated with antipsychotic medications. Additionally, Auris Medical is developing AM-102 for tinnitus treatment. The company collaborates with academic institutions and other entities such as INSERM and Xigen S.A. to enhance its product offerings, including drug delivery devices for local administration to the inner ear. Founded in 1998, Auris Medical is headquartered in Hamilton, Bermuda.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

Esmertec AG is a prominent independent software company that specializes in Java solutions and technologies tailored for mass-market devices, including mobile multimedia phones, personal digital assistants, and home multimedia systems. The company's Java device platforms are designed to assist terminal manufacturers, operators, and content providers in delivering a variety of customized multimedia services to a broad consumer audience. Additionally, Esmertec develops mobile browsing application software and provides carrier-grade platforms and services, including unstructured supplementary service data messaging and browsing services, particularly in France. Through its innovative offerings, Esmertec plays a significant role in enhancing the user experience across various mobile and multimedia applications.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

Esmertec AG is a prominent independent software company that specializes in Java solutions and technologies tailored for mass-market devices, including mobile multimedia phones, personal digital assistants, and home multimedia systems. The company's Java device platforms are designed to assist terminal manufacturers, operators, and content providers in delivering a variety of customized multimedia services to a broad consumer audience. Additionally, Esmertec develops mobile browsing application software and provides carrier-grade platforms and services, including unstructured supplementary service data messaging and browsing services, particularly in France. Through its innovative offerings, Esmertec plays a significant role in enhancing the user experience across various mobile and multimedia applications.